U.S. Stock News

NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher’s New Sweden Lab Deepens Role In Global Drug Development

Thermo Fisher Scientific (NYSE:TMO) has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden. The facility is designed to support pharmaceutical and biotechnology companies across all stages of drug development. The lab is connected to Thermo Fisher Scientific's global network of drug development services. Thermo Fisher Scientific, trading at around $449.37, sits at the crossroads of tools, services, and outsourced support that many drug developers rely on. The stock is...
NasdaqGS:HUT
NasdaqGS:HUTSoftware

Did Hut 8’s US$16 Million Water Build-Out at River Bend Just Shift Its (HUT) Investment Narrative?

Earlier this week, Hut 8 Corp. agreed to invest about US$16,000,000 to expand West Feliciana Parish’s water system to support its River Bend AI data center campus, funding a new well, eight miles of water mains, and system upgrades that will be handed to the parish at no cost to taxpayers. This privately funded infrastructure build-out not only enables Hut 8’s closed-loop cooled AI facilities, but also boosts water capacity and reliability for more than 4,000 households and over 200 local...
NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Relay Therapeutics (RLAY) Is Up 6.9% After Zovegalisib Phase 2 Data And Equity Raise - Has The Bull Case Changed?

Earlier in May 2026, Relay Therapeutics completed a US$275,000,004 follow-on equity offering at US$12 per share after releasing initial Phase 2 ReInspire data showing zovegalisib achieved a 60% volumetric response rate and broad symptom improvement in PIK3CA‑driven vascular anomalies with a safety profile supportive of chronic dosing. An interesting angle is that zovegalisib is being advanced simultaneously in rare vascular anomalies and in an ongoing Phase 3 program for metastatic breast...
NasdaqGS:TARS
NasdaqGS:TARSPharmaceuticals

Assessing Tarsus Pharmaceuticals (TARS) Valuation After New TP-05 Phase 2b Lyme Disease Trial Update

Clinical update on TP-05 puts Tarsus Pharmaceuticals (TARS) in focus Tarsus Pharmaceuticals (TARS) recently updated investors on its ongoing Phase 2b trial of TP-05, an oral tablet being tested to help prevent Lyme disease in high risk individuals. See our latest analysis for Tarsus Pharmaceuticals. The recent TP-05 update comes as Tarsus trades at US$63.48, with the share price down 21.41% year to date but a 1 year total shareholder return of 47.73% and a very large 3 year total shareholder...
NYSE:TFC
NYSE:TFCBanks

Truist Financial (TFC) Valuation Check After Recent Share Price Weakness And Undervaluation Signal

Recent performance snapshot Truist Financial (TFC) has drawn investor attention after its share price closed at US$47.89, with the stock down about 6% over the past month and roughly 8% over the past 3 months. See our latest analysis for Truist Financial. While the share price is down 6.2% over the past month and 8.5% over the past quarter, the 1 year total shareholder return of 26.8% and 3 year total shareholder return of 83.0% point to stronger longer term momentum. If Truist Financial has...
NasdaqGM:HPK
NasdaqGM:HPKOil and Gas

A Look At HighPeak Energy (HPK) Valuation As Oil Prices Break Above $100 On Geopolitical Tensions

Oil price shock and HighPeak Energy's stock reaction HighPeak Energy (HPK) moved higher after crude oil prices climbed above $100 a barrel, as mounting geopolitical tensions and potential Strait of Hormuz disruptions fed through to oil linked equities and heightened day to day volatility. See our latest analysis for HighPeak Energy. Beyond the latest oil price shock, HighPeak Energy’s share price has shown strong short term momentum, with a 30 day share price return of 20.46% and a year to...
NYSE:RMD
NYSE:RMDMedical Equipment

How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem

On 19 May 2026, ResMed and Oura announced a partnership that connects Oura Ring Gen3 and Ring 4 members in the U.S. to ResMed’s sleep education tools, assessments, and options to link with independent healthcare providers. This collaboration uniquely bridges consumer wearable sleep data with clinical sleep resources, aiming to help address undiagnosed conditions such as obstructive sleep apnea. Next, we’ll examine how integrating Oura’s consumer wearables data with ResMed’s clinical sleep...
NYSE:CB
NYSE:CBInsurance

A Look At Chubb (CB) Valuation After Dividend Increase And US$7.5b Buyback Authorization

Chubb (CB) has drawn fresh attention after shareholders approved a 5.2% dividend increase and a new US$7.5b share repurchase program, putting capital return policy firmly in focus for investors. See our latest analysis for Chubb. At a share price of US$330.26, Chubb’s recent news on dividends and buybacks comes after a steady year to date. A 6.51% year to date share price return and a 16.53% 1 year total shareholder return suggest that momentum has been building rather than fading. If you are...
NasdaqCM:ASTH
NasdaqCM:ASTHHealthcare

A Look At Astrana Health (ASTH) Valuation After Q1 Earnings And AI Driven Full Risk Expansion

Astrana Health (ASTH) has been in focus after Q1 earnings, where management highlighted strong revenue growth, increasing use of full risk contracts, and progress integrating the Prospect acquisition alongside its AI driven care platform. See our latest analysis for Astrana Health. Astrana Health's share price sits at $37.38 after a recent 1 day decline of 3.56% and 7 day fall of 4.55%. However, the 30 day share price return of 14.84% and 90 day gain of 88.22% highlight strong recent...
NasdaqGS:GENB
NasdaqGS:GENBBiotechs

A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment

Nvidia’s recent US$10.4 million investment in Generate Biomedicines (GENB) has drawn fresh attention to the AI-focused biotech, as investors assess what this backing could mean for its drug development pipeline. See our latest analysis for Generate Biomedicines. The Nvidia investment comes after a volatile stretch for Generate Biomedicines, with a 1-day share price return of 7.37% to US$13.98, a 30-day share price return of 10.34% and a year to date share price return of 10.51%. This comes...
NasdaqGS:COHU
NasdaqGS:COHUSemiconductor

Is Cohu (COHU) Quietly Reframing Its AI Infrastructure Story With This DiamondX GaN Test Win?

Cohu, Inc. recently reported that a semiconductor manufacturer placed multiple orders totaling approximately US$5,000,000 for its DiamondX test platform, which supports high‑current, ultra‑low resistance measurements and scalable multi‑site throughput for gallium nitride power devices in AI data center power architectures. This win highlights how Cohu is tying its advanced power test capabilities directly to the specific needs of AI data center power conversion, from AC‑DC front ends to...
NYSEAM:PRK
NYSEAM:PRKBanks

Earnings Beat And Special Dividend Could Be A Game Changer For Park National (PRK)

Park National Corporation recently reported a past-quarter earnings beat and announced both a regular dividend increase and a special dividend for shareholders. This combination of stronger-than-expected results with an enhanced and one-off cash return highlights management’s focus on reinforcing shareholder income. We’ll now examine how Park National’s earnings surprise and special dividend shape its investment narrative for income-focused and quality-oriented investors. Uncover the next...
NYSE:FIG
NYSE:FIGSoftware

Figma (FIG) Valuation Check After Strong Q1 Beat Raised Guidance And AI Growth Momentum

Figma (FIG) is back in focus after first quarter 2026 results topped earnings and revenue expectations, with the company lifting full year revenue guidance and highlighting strong adoption of its AI driven design tools. See our latest analysis for Figma. Despite the strong Q1 reaction, with the stock rallying on earnings and guidance, Figma’s recent share price return tells a mixed story. The 1 month share price return is 15.33%, but the year to date share price return is down 42.60%. This...
NasdaqGS:VISN
NasdaqGS:VISNCommunications

Should DOCSIS 4.0 and Wi-Fi 7 Tailwinds Reshape How Vistance Networks (VISN) Investors View Risk?

Recently, industry research highlighted how Vistance Networks is benefiting from broad digitalization trends, with its Aurora segment tied to the DOCSIS 4.0 upgrade cycle and its RUCKUS unit supported by rising Wi-Fi 7 demand as operators and enterprises modernize networks. This underscores Vistance’s position at the center of major broadband and enterprise networking refresh cycles, where technology standards shifts can meaningfully influence long-term revenue mix and customer...
NYSE:PFSI
NYSE:PFSIDiversified Financial

How Escalating Legal Probes Into Disclosures Will Impact PennyMac Financial Services (PFSI) Investors

In recent months, PennyMac Financial Services has faced multiple securities law investigations and class action preparations over allegedly misleading disclosures about mortgage refinance recapture rates and business performance, following weaker servicing segment results and heightened competitive pressures. At the same time, a large portion of loans in a new RMBS deal were originated by PennyMac, highlighting how its operational footprint in mortgage origination contrasts with growing...
NYSE:DCO
NYSE:DCOAerospace & Defense

Ducommun (DCO) Is Down 5.7% After Strong Q1, New Credit Facility And ESOP Shelf Filing

In May 2026, Ducommun reported first-quarter sales of US$209.02 million and net income of US$9.92 million, while also securing a new US$650 million credit facility and filing an US$87.16 million shelf registration for ESOP-related common stock. Management highlighted a sharp improvement in commercial aerospace and reaffirmed its intent to pursue acquisitions, emphasising valuation discipline and the goal of enhancing shareholder value. Now we’ll examine how Ducommun’s stronger quarterly...
NYSE:MTDR
NYSE:MTDROil and Gas

Matador Resources Expands Delaware Basin Acreage And Extends Drilling Runway

Matador Resources (NYSE:MTDR) has agreed to acquire over 5,000 net undeveloped acres in the Delaware Basin. The transaction expands the company’s core acreage position and adds to its future drilling inventory. The newly acquired acreage is described as high quality and directly increases Matador’s reserve base. For investors tracking NYSE:MTDR, this acreage deal comes with the stock around $56.09 and a return of 29.4% year to date and 32.6% over the past year. Over a 5-year period, the...
NYSE:CUBE
NYSE:CUBESpecialized REITs

How Investors Are Reacting To CubeSmart (CUBE) Dividend Hike, Earnings Beat And NYC Recovery Update

Earlier this week, CubeSmart’s board declared a past quarterly dividend of US$0.53 per share for the period ended June 30, 2026, payable on July 15 to shareholders of record as of July 1. Alongside the dividend, investors reacted to CubeSmart’s Q1 2026 earnings beat and upbeat New York City operating update, which highlighted a strong recovery in same-store revenue and net rentals. We’ll now examine how the Q1 earnings beat and improving New York City fundamentals may reshape CubeSmart’s...
NYSE:BMI
NYSE:BMIElectronic

The Bull Case For Badger Meter (BMI) Could Change Following Q1 Sales Drop And Fraud Probes – Learn Why

Earlier in 2026, Badger Meter disclosed a year-over-year 9% first-quarter sales decline, especially in utility water products, prompting law firms to investigate potential securities violations tied to its communications on demand and growth. At the same time, the company pressed ahead with its 2026 Investor Day webcast to outline its smart water strategy and long-term framework, underscoring a gap between its growth messaging and recent operational headwinds. Against this backdrop of weaker...
NasdaqGS:LEGN
NasdaqGS:LEGNBiotechs

A Look At Legend Biotech (LEGN) Valuation After Its Strong Q1 2026 Revenue And Narrower Net Loss

Legend Biotech (LEGN) drew fresh attention after reporting first quarter 2026 results, with revenue of US$305.1 million, a narrower net loss of US$54.3 million, and reduced loss per share versus a year earlier. See our latest analysis for Legend Biotech. The quarterly update comes after a sharp 54.47% 90 day share price return and a 30.13% year to date share price gain, contrasting with a 3.65% decline in 1 year total shareholder return and a 55.77% decline over 3 years. This suggests recent...
NasdaqGS:ADUS
NasdaqGS:ADUSHealthcare

A Look At Addus HomeCare (ADUS) Valuation After Recent Share Price Weakness

Addus HomeCare (ADUS) has drawn investor attention after recent trading left the stock around $93.26, with performance mixed over the past year and fundamentals that highlight its position in US home-based care services. See our latest analysis for Addus HomeCare. The recent move to around $93.26 comes after a modest 7 day share price return of 0.92%. However, the 90 day share price return is down 19.24%, and the 1 year total shareholder return is down 16.38%. This points to fading momentum...
NYSE:CWT
NYSE:CWTWater Utilities

A Look At California Water Service Group’s (CWT) Valuation After Its 2025 Sustainability Report

California Water Service Group (CWT) has put its 2025 Sustainability Report at center stage, detailing greenhouse gas emission cuts, full water quality compliance, and third party recognition that may influence how investors think about the stock’s ESG profile. See our latest analysis for California Water Service Group. Despite the fresh sustainability accolades and leadership changes, the stock’s 30 day share price return is down 6.47%, and the 1 year total shareholder return is down 5.21%,...
NYSE:STT
NYSE:STTCapital Markets

Did Earnings Strength And A Steady Dividend Just Shift State Street's (STT) Investment Narrative?

State Street recently reported strong fourth-quarter 2025 results, highlighted by robust net interest income, margin expansion despite higher operating costs, and a growing backlog of new mandates totaling US$3.60 trillion, while also continuing share repurchases. In parallel, the company has reinforced its capital return profile with a US$0.84 per-share common dividend announced for July 2026 and ongoing preferred dividends, while multiple executives recorded routine tax-related share...
NYSE:ASB
NYSE:ASBBanks

A Look At Associated Banc-Corp (ASB) Valuation After Dallas Commercial Banking Expansion

Associated Banc-Corp (ASB) is expanding its commercial banking footprint in Dallas by adding a dedicated Corporate and Commercial Banking team, hiring experienced local bankers, and doubling its Preston Center office to support broader services. See our latest analysis for Associated Banc-Corp. At a share price of $28.05, Associated Banc-Corp has seen an 8.89% year to date share price return, while its 1 year total shareholder return of 26.09% and 3 year total shareholder return of about 2x...